Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS

Molecular Systems Biology

Volumn 8, Issue , 2012, Pages

  Stelniec Klotz, Iwona ^a   Legewie, Stefan ^b   Tchernitsa, Oleg ^a   Witzel, Franziska ^a,c   Klinger, Bertram ^a,c   Sers, Christine ^a   Herzel, Hanspeter ^c   Blüthgen, Nils ^a,c   Schäfer, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institute for Molecular Biology   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

cancer systems biology; modular response analysis; oncogenes; ovarian carcinoma model; signal transduction

Indexed keywords

FOS LIKE ANTIGEN 1 PROTEIN; FUNCTIONAL GROUP; HIGH MOBILITY GROUP A2 PROTEIN; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; PROTEIN FOS; PROTEIN INTERACTING WITH PROTEIN KINASE C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR OTX; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; KLF6 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; ONCOPROTEIN; PROTEIN C FOS; RAS PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FRA 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SILENCING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE ENGINEERING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; ONCOGENE RAS; OVARY; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, RAS; HMGA2 PROTEIN; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICROARRAY ANALYSIS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RAS PROTEINS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84864831454     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.1038/msb.2012.32     Document Type: Article

References (57)

1. Adams AT, Auersperg N (1981) Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res 41: 2063-2072 (Pubitemid 11111396)
2. Adams AT, Auersperg N (1985) A cell line, ROSE 199, derived from normal rat ovarian surface epithelium. Exp Cell Biol 53: 181-188 (Pubitemid 15036715)
3. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, ZeiselA,Amit I, Zwang Y, Enerly E, RussnesHG, Biagioni F, Mottolese M, Strano S, Blandino G, Borresen-Dale AL, Pilpel Y, Yakhini Z, Segal E et al (2010) EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal 3: ra43
4. Basseres DS, Ebbs A, Levantini E, Baldwin AS (2010) Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 70: 3537-3546
5. Battista S, de NF, Fedele M, Chiappetta G, Scala S, Vallone D, Pierantoni GM, Mega T, Santoro M, Viglietto G, Verde P, Fusco A (1998) Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene 17: 377-385 (Pubitemid 28383014)
6. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, NijkampW,Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437 (Pubitemid 38419689)
7. Bhalla US, Iyengar R (1999) Emergent properties of networks of biological signaling pathways. Science 283: 381-387
8. Bluthgen N, Legewie S, Kielbasa SM, Schramme A, Tchernitsa O, Keil J, Solf A, Vingron M, Schafer R, Herzel H, Sers C (2009) A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-Transformed fibroblasts. FEBS J 276: 1024-1035
9. Breccia M, Frustaci AM, Cannella L, Soverini S, Stefanizzi C, Federico V, Grammatico S, Santopietro M, Alimena G (2009) Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? Cancer Chemother Pharmacol 64: 195-197
10. Brem R, Certa U, Neeb M, Nair AP, Moroni C (2001) Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model. Oncogene 20: 2854-2858 (Pubitemid 32549842)
11. Busch AC, Scheffer C, Basson AH (2009) Development and testing of a prototype reflex measurement system employing artificial neural networks. Comput Methods Programs Biomed 94: 15-25
12. Busch H, Camacho-Trullio D, Rogon Z, Breuhahn K, Angel P, Eils R, Szabowski A (2008) Gene network dynamics controlling keratinocyte migration. Mol Syst Biol 4: 199
13. Cantone I, Marucci L, Iorio F, Ricci MA, Belcastro V, Bansal M, Santini S, di BM, di BD, CosmaMP (2009) Ayeast synthetic network for in vivo assessment of reverse-engineering and modeling approaches. Cell 137: 172-181
14. Casalino L, Bakiri L, Talotta F,Weitzman JB, Fusco A, Yaniv M, Verde P (2007) Fra-1 promotes growth and survival in RAS-Transformed thyroid cells by controlling cyclin A transcription. EMBO J 26: 1878-1890 (Pubitemid 46624039)
15. Casalino L, De Cesare D, Verde P (2003) Accumulation of Fra-1 in rastransformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 23: 4401-4415 (Pubitemid 36666439)
16. Cleynen I, Van de Ven WJ (2008) The HMGA proteins: a myriad of functions (Review). Int J Oncol 32: 289-305 (Pubitemid 351188295)
17. Corcoran RB, Settleman J, Engelman JA (2011) Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2: 336-346
18. de HT, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L, Perera M, Corte G, Wirths O, van SP, Pietsch T, Troost D, Baas F, Versteeg R, Kool M (2006) OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol 65: 176-186
19. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA (2006) Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 12: 3730-3739 (Pubitemid 44000254)
20. Dwivedi PP, Anderson PH, Tilley WD, May BK, Morris HA (2007) Role of oncoprotein growth factor independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): a comparative analysis in human prostate cancer and kidney cells. J Steroid Biochem Mol Biol 103: 742-746 (Pubitemid 46401320)
21. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin Jr AS (1997) Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272: 24113-24116 (Pubitemid 27418602)
22. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Bluthgen N (2011) Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol 7: 489
23. Gardner TS, di BD, Lorenz D, Collins JJ (2003) Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301: 102-105 (Pubitemid 36801571)
24. Goentoro L, Shoval O, Kirschner MW, Alon U (2009) The incoherent feedforward loop can provide fold-change detection in gene regulation. Mol Cell 36: 894-899
25. Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN (1996) The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal. Mol Cell Biol 16: 6263-6272 (Pubitemid 26360986)
26. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, Friese C, Kielbasa SM, Ungethum U, Lund P, Knosel T, KemmnerW, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperling S, Sers C, Royer HD et al (2010) Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathwaydependent gene signatures in colorectal cancer cells. PLoS Genet 6: e1001231
27. Kanzler B, Viallet JP, Le MH, Boncinelli E, Duboule D, Dhouailly D (1994) Differential expression of two different homeobox gene families during mouse tegument morphogenesis. Int J Dev Biol 38: 633-640
28. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310 (Pubitemid 37328783)
29. Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531 (Pubitemid 351881844)
30. Kholodenko BN, Kiyatkin A, Bruggeman FJ, Sontag E, Westerhoff HV, Hoek JB (2002) Untangling the wires: a strategy to trace functional interactions in signaling and gene networks. Proc Natl Acad Sci USA 99: 12841-12846
31. Legewie S, Herzel H, Westerhoff HV, Bluthgen N (2008) Recurrent design patterns in the feedback regulation of the mammalian signalling network. Mol Syst Biol 4: 190
32. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I (2008) NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8: 41
33. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-Time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods 25: 402-408 (Pubitemid 34164012)
34. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292 (Pubitemid 40227997)
35. Madar A, Greenfield A, Ostrer H, Vanden Eijnden E, Bonneau R (2009) The Inferelator 2.0: a scalable framework for reconstruction of dynamic regulatory network models. Conf Proc IEEE Eng Med Biol Soc 2009: 5448-5451
36. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS, Mayo MW (2000) Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 20: 1626-1638 (Pubitemid 30100182)
37. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa OI (2008) HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123: 348-356 (Pubitemid 351842019)
38. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla FR, Califano A (2006) ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 20(7 Suppl 1): S7
39. Mechta F, Lallemand D, Pfarr CM, Yaniv M (1997) Transformation by ras modifies AP1 composition and activity. Oncogene 14: 837-847 (Pubitemid 27100028)
40. Milde-Langosch K (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41: 2449-2461 (Pubitemid 41540622)
41. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4: 556-564
42. Narla G, DiFeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA et al (2005) A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65: 1213-1222 (Pubitemid 40270146)
43. Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, Aruleba S, Balija V, O'Shaughnessy A, Gnoj L, Scobie K, Chang K, Westbrook T, Cleary M, Sachidanandam R, McCombie WR, Elledge SJ, Hannon GJ (2004) A resource for large-scale RNAinterference-based screens in mammals. Nature 428: 427-431 (Pubitemid 38419688)
44. Santos SD, Verveer PJ, Bastiaens PI (2007) Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 9: 324-330 (Pubitemid 46344612)
45. SchaffnerW,Weissmann C (1973) A rapid and sensitive method for the determination of protein in dilute solution. Anal Biochem 56: 502-514
46. Schmidt M, Lipson H (2009) Distilling free-form natural laws from experimental data. Science 324: 81-85
47. Suzuki H, Forrest AR, van NE, Daub CO, Balwierz PJ, Irvine KM, Lassmann T, Ravasi T, Hasegawa Y, de Hoon MJ, Katayama S, Schroder K, Carninci P, Tomaru Y, Kanamori-Katayama M, Kubosaki A, Akalin A, Ando Y, Arner E, Asada M et al (2009) The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet 41: 553-562
48. Tchernitsa OI, Sers C, Geflitter A, Schafer R (2005) Effects of ras signaling on gene expression analyzed by customized microarrays. Methods Enzymol 407: 373-387 (Pubitemid 43815963)
49. Tchernitsa OI, Sers C, Geflitter A, Schäfer R (2006) Oligonucleotide microarrays for studying the effects of Ras signal transduction on the genetic program. Signal Transduction 6: 209-218 (Pubitemid 44013865)
50. Tchernitsa OI, Sers C, Zuber J, Hinzmann B, Grips M, Schramme A, Lund P, Schwendel A, Rosenthal A, Schafer R (2004) Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 23: 4536-4555 (Pubitemid 38850403)
51. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121 (Pubitemid 32397092)
52. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A, Verde P (1997) Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 16: 5310-5321 (Pubitemid 27380139)
53. van Dam H., Castellazzi M (2001) Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 20: 2453-2464 (Pubitemid 32531302)
54. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB (2007) Deciphering AP-1 function in tumorigenesis: fra-Ternizing on target promoters. Cell Cycle 6: 2633-2639 (Pubitemid 350224046)
55. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M (2009) HMGA2 maintains oncogenic RAS-induced epithelialmesenchymal transition in human pancreatic cancer cells. Am J Pathol 174: 854-868
56. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL (2008) Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134: 1521-1531 (Pubitemid 351615359)
57. Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M, Sers C, Rosenthal A, Schafer R (2000) A genomewide survey of RAS transformation targets. Nat Genet 24: 144-152 (Pubitemid 30094714)